Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Research material

or [[:Category:Lipid-lowering_agents|Lipid-lowering agent]]

Use the filters below to narrow your results.

Other values:

None (130) · (none, never marketed) (1) · Altoprev (ER), Mevacor (discontinued US); mostly generic (1) · Crestor, Ezallor (1) · Lipitor (1) · Lovaza, Omtryg (1) · Niaspan (ER, Rx), Niacor (IR, Rx); huge OTC presence (1) · O-DSMT (1) · Pravachol (1) · Repatha (1) · Tricor, Lipofen, Antara, Fenoglide, Lofibra, Triglide, Trilipix (fenofibric acid) (1) · Vascepa (1) · Zetia (1) · Zocor (1)

5-HT2A agonist (26) · Monoamine releasing agent (9) · GABAA positive allosteric modulator (8) · None (7) · CB1/CB2 agonist (7) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Serotonin/norepinephrine/dopamine releasing agent (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · NMDA antagonist (2) · Prodrug of GHB (2)

Other values:

None (131) · 10 mg PO once daily, with or without food (1) · 10-20 mg PO once daily (1) · 10-20 mg PO once daily (5 mg in Asian ancestry, elderly, hypothyroidism, or strong CYP/SLCO1B1 interactions) (1) · 10-20 mg PO once daily in the evening (40 mg starting allowed for high CV risk) (1) · 140 mg SC every 2 weeks OR 420 mg SC monthly (3 consecutive injections 5 minutes apart due to volume) (1) · 2 g PO BID with meals (4 g/d total) (1) · 20 mg PO once daily with the evening meal; titrate to 40-80 mg/d (1) · 4 g PO daily (as 4 x 1 g capsules once daily, or 2 capsules BID) (1) · 40 mg PO once daily (10-20 mg in elderly, hepatic impairment, or strong drug interactions) (1) · Niaspan ER 500 mg PO at bedtime, titrate weekly to 1-2 g/d; flushing-protective aspirin 30-60 minutes before dose; pellagra replacement 100-500 mg/d (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) · Varies by salt form and brand; e.g., Tricor 145 mg PO daily; reduce to 48 mg in renal impairment (1)

None (131) · 0.5 g, 1 g capsules (1) · 1 g soft gelatin capsules containing ~465 mg EPA + ~375 mg DHA as ethyl esters (1) · 10 mg tablet; also as fixed-dose combinations with simvastatin (Vytorin) and atorvastatin (Liptruzet, withdrawn US 2015 but generics exist) (1) · 10 mg, 20 mg, 40 mg, 80 mg tablets (2) · 10, 20, 40 mg tablets; 20, 40, 60 mg ER tablets (1) · 140 mg/mL single-use prefilled syringe and SureClick autoinjector; Pushtronex 420 mg/3.5 mL on-body infusor (1) · 5, 10, 20, 40 mg tablets (1) · 5, 10, 20, 40, 80 mg tablets; 4 mg/mL oral suspension (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) · Multiple non-bioequivalent fenofibrate and fenofibric acid formulations: 48-200 mg (1) · OTC IR niacin 50-500 mg tablets; Niaspan ER 500, 750, 1000 mg tablets; "no-flush" niacin (inositol hexaniacinate, lacks evidence) (1)

None (131) · 10 mg/d (1) · 2 g/d (Niaspan); higher off-label use historical (1) · 4 g/d (2) · 40 mg/d (rarely needed; 40 mg restricted to patients not at goal on 20 mg) (1) · 40 mg/d standard; 80 mg/d restricted to patients tolerating 80 mg for ≥12 months without myopathy (post-SEARCH 2011 FDA restriction) (1) · 420 mg/month (1) · 80 mg/d (2) · 80 mg/d (40 mg/d if combined with diltiazem, verapamil, danazol; lower limits with various interactions) (1) · Formulation-specific (e.g., 145 mg/d Tricor, 200 mg/d Lipofen) (1) · N/A (never approved) (1)

None (131) · intranasal; rectal and IV reported. (1) · Oral (11) · Subcutaneous (1) · sublingual (1)

None (131) · LDL lowering at 1 week, max by 4 weeks (1) · LDL lowering at 2 weeks, max by 4 weeks (3) · LDL lowering at 2 weeks, max by 4 weeks; cardiovascular benefit months to years (1) · LDL lowering within 2 weeks (1) · LDL reduction ~50-60% from baseline at 1-2 weeks (1) · Lipid changes 4-8 weeks (1) · Triglyceride lowering at 2-4 weeks; max at 8 weeks (1) · Triglyceride lowering at 4-8 weeks (1) · Triglyceride lowering at 4-8 weeks; CV benefit emerges over months (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (131) · 12 hours (1) · 2-4 weeks per dose (1) · 24 hours (6) · 24 hours (evening dosing aligns with overnight HMG-CoA reductase peak) (1) · 24-48 hours per dose (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · Daily dosing (1)

None (131) · 14 hours (parent); 20-30 hours including active ortho- and para-hydroxylated metabolites'"`UNIQ--ref-0000001B-QINU`"' (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · Not well characterized; tissue incorporation over weeks'"`UNIQ--ref-00000051-QINU`"' (1) · ~1 hour (IR niacin); ER formulations extend functional duration'"`UNIQ--ref-00001038-QINU`"' (1) · ~11-17 days'"`UNIQ--ref-0000147F-QINU`"' (1) · ~19 hours'"`UNIQ--ref-000000FC-QINU`"' (1) · ~2 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect lasts 24 hours via target turnover'"`UNIQ--ref-0000017A-QINU`"' (1) · ~2-3 hours (parent); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-000003D5-QINU`"' (1) · ~2-4 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-00000807-QINU`"' (1) · ~20 hours (fenofibric acid, the active metabolite)'"`UNIQ--ref-000004AD-QINU`"' (1) · ~22 hours (parent + active glucuronide)'"`UNIQ--ref-00000450-QINU`"' (1) · ~89 hours (EPA, the active metabolite)'"`UNIQ--ref-000013D1-QINU`"' (1)

None (131) · <5% (extensive hepatic first-pass; food enhances absorption of IR, hence the evening-meal dosing)'"`UNIQ--ref-00000808-QINU`"' (1) · <5% (extensive hepatic first-pass; statin pharmacology is hepatocellular, not systemic)'"`UNIQ--ref-0000017B-QINU`"' (1) · High (oral; food enhances)'"`UNIQ--ref-00001039-QINU`"' (1) · Improved with food'"`UNIQ--ref-00000052-QINU`"' (1) · Increased with food (varies by formulation; the micronized and nanocrystal forms are less food-dependent)'"`UNIQ--ref-000004AE-QINU`"' (1) · Not formally characterized in humans. (1) · Substantially improved with high-fat meal; take with food'"`UNIQ--ref-000013D2-QINU`"' (1) · Variable (oral; rapidly conjugated to active glucuronide; food does not affect)'"`UNIQ--ref-00000451-QINU`"' (1) · ~14% (extensive hepatic first-pass)'"`UNIQ--ref-0000001C-QINU`"' (1) · ~17% (oral; food slightly reduces absorption)'"`UNIQ--ref-000003D6-QINU`"' (1) · ~20% (oral; hydrophilic, minimal CYP metabolism, mostly excreted unchanged in bile)'"`UNIQ--ref-000000FD-QINU`"' (1) · ~72% from SC depot'"`UNIQ--ref-00001480-QINU`"' (1)

None (131) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Limited data.[[[Pharmacopedia:Citation needed|citation needed]]] (2) · Limited data; generally avoided particularly in combination with statin.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; generally avoided unless triglyceride pancreatitis risk is high.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited human data[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Pharmacologic doses generally avoided in pregnancy; vitamin doses fine.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021. Use individualized.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021. Use individualized; lactation generally avoided.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021.[[[Pharmacopedia:Citation needed|citation needed]]] (3)

None (132) · OTC (low-dose, dietary supplement) and [[USLegal:Prescription only|Rx-only]] (Niaspan ER) in US (1) · [[USLegal:Prescription only|Rx-only]] in US (10)

1

2

3

4

5

A

B

C

D

E

F

G

H

I

J

L

M

N

O

P

R

S

T

U